

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.:  
L74899DL1993PLC056594

To

Date: 19.01.2021

**BSE Limited**  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street,  
Mumbai-400001

Scrip Code: 531146

**Subject: Intimation under SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015**

Dear Sir/Madam

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, intimation is hereby given that Medicamen Biotech Limited has planned a partial shutdown of its plant at Bhiwadi (Rajasthan) for 4 to 6 weeks. During the shutdown following 3 areas will be taken up for upgradation as per CGMP norms, which are expected to be completed in 4 to 6 weeks.

1. Beta Lactum block :- All the three areas for beta lactum block i.e Powder for suspension, Tablets section and Capsule Area including Dispensing Area and Warehouse for API are being taken up for upgradation as per regulated market.
2. Non Beta Powder for suspension block – complete revamp of Non Beta pfs area with increased capacity and dedicated AHU with dehumidification as per regulated market requirements
3. ORS Manufacturing area – This area is being converted to install additional auto plant of liquid fabrication for 2.5 KL capacity along with auto mono block Liquid filling / sealing machine with auto cartoner .

All the above upgradation shall take 4-6 weeks. During this upgradation the production/activities shall remain partially suspended


The upgradation would not only enable MBL to prepare for regulated market but also provide next level of growth in terms of good volume business with better margins.

This is for your kind attention and records.

Kindly acknowledge the receipt.

Thanking You

Yours Faithfully  
for Medicamen Biotech Limited

  
**Parul Choudhary**  
ACS44157  
Company Secretary

